CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

PHASE II CLINICAL TRIAL OF SYH2062 INJECTION FOR THE TREATMENT OF ADULT ESSENTIAL HYPERTENSION OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHINA

The Board of Directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the Phase II clinical trial (SYH2062–003) of SYH2062 Injection (the "**Product**") developed by the Group for the treatment of adult essential hypertension, has been officially initiated at the first centre in China.

The Product is a chemically modified, double-stranded small interfering RNA (siRNA) consisting of 21 to 23 nucleotides in length, utilising N-acetylgalactosamine (GalNAc) conjugation technology to achieve liver-targeted delivery. The Product can specifically silence the angiotensinogen (AGT) gene, inhibit the expression of the corresponding protein, and alleviate the over-activation of the renin-angiotensin-aldosterone system (RAAS), thereby exerting effective pathway inhibition and delivering long-term stable blood pressure control.

Previously, the Product obtained the Notice of Approval for Clinical Trial of Drug from the National Medical Products Administration of the People's Republic of China in December 2024. Currently, the Group has obtained Phase I clinical trial data in hypertensive patients, which have preliminarily validated its safety profile as well as pharmacokinetic and pharmacodynamic characteristics in humans. The Product is expected to bring longer-lasting and more stable blood pressure-lowering benefits to adult patients with essential hypertension in China.

This Phase II clinical trial is a multi-centre, randomised, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of the Product in subjects with mild-to-moderate essential hypertension. Currently, the recruitment and screening of trial subjects are actively underway.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 29 July 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.